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Summary
We studied the humoral response of mice immunized with soluble CD4-rgp120 complex, testing
polyclonal and monoclonal antibodies (mAbs) with the aim of identifying molecular changes
that take place after the first interaction between human immunodeficiency virus and the cell
surface. The antisera had a paradoxically high syncytia-blocking titer associated with anti-CD4
specificity, while their capacity to inhibit CD4-gp120 binding was relatively modest . One of
the mAbs produced from these responders blocks syncytia formation but does not inhibit CD4
interaction with gp120. Apparently, this mAb interacts with the CD4 moiety of CD4-gp120
complex and prevents a post-binding event necessary for membrane fusion and viral infection .
T
he protein CD4 on the surface ofTh cells and macro-
phages was identified as the receptor forHIV (1, 2), and
its capacity to bind the viral envelope protein gp120 with
high affinity was subsequently demonstrated (3) . While this
interaction is essential for the virus to eventually infect the
target cells, there are indications,that theCD4-gp120 binding
initiates a chain of events, some of which may be equally im-
portant for virus penetration and infection . This is supported
by claims thatsome antibodies directed against determinants
positioned far from the CD4-binding site on gp120 (4) or
against gp41 (5, 6) exhibit neutralizing capacity. This prop-
erty is analogous to that of antienvelope glycoprotein anti-
bodies in the case of herpes and EBV (7, 8) . We have ob-
served a dissociation ofneutralizing capacity and gp120binding
inhibition in anti-CD4 antibodies ; this indicates a symmetrical
relationship suggesting that events and/or signals occurring
at the level of CD4 may represent such post-binding steps
on the side of the cellmembrane. For example, after binding
to gp120, changes in conformation could reshuffle the fine
antigenic structure, and new or modified epitopes associated
with distinct functional states of the moleculemaycome into
existence. Antibody binding to such induced or unmasked
determinants could result in interruption ofthe chain ofevents
leading to viral penetration of the cell .
With the aim of defining post-binding markers, we have
immunized mice with complexes of recombinant gp120 and
CD4, and have obtained high titers of syncytia-blocking an-
tibodies mainly directed at the CD4 moiety. In this report,
we describe specificity and function of polyclonal andmono-
clonal antibodies resulting from these experiments, notably
of those mAbs that inhibit syncytia formation by a mecha-
nism different from blocking gp120-CD4 binding.
Materials and Methods
Recombinant Molecules.
￿
Soluble rCD4, CD4 immunoadhesin
(containing VI and V2 domains ofCD4 spliced to CH2 and CH3
domains of human IgG) (9), and rgp120 were produced by Genen-
tech Inc. (South San Francisco, CA) .
Animals.
￿
BALB-c female mice 10-15wk old (TheJackson Lab-
oratory Bar Harbor, ME) were used both for immunization and
for production of mAbs.
Immunizations.
￿
Mice were injected intraperitoneally with an-
tigen emulsified in CFA (Difco Laboratories Inc., Detroit, MI) .
The antigens and doses were CD4, 12.8 ug/mouse ; gp120, 10
ug/mouse; and CD4-gp120, 12.8 EcgCD4 and 10,ug gp120, thor-
oughly mixed and incubated for 20 min, and then emulsified in
CFA . The mice were bled before immunization and every week
after, for 13 wk . Serum samples were stored at -20°C .
Enzymes and Substrates.
￿
Alkaline phosphatase and glutaralde-
hyde, used to label antibodies for ELISAs, and substrate paranitro-
1143
￿
J . Exp. Med . ® The Rockefeller University Press " 0022-1007/90/10/1143/08 $2.00
Volume 172 October 1990 1143-1150phenylphosphate (PNPP)' were acquired from Sigma Chemical
Co. (St. Louis, MO).
mAbs.
￿
Our own mAbs mentioned in this paper are F-91-36,
F-91-55, and F-91-94, hereafter called 36, 55, and 94, respectively.
They are derived from a fusion ofmouse 91, immunized with CD4-
gp120 complex. All these are IgG1 subclass.
Antibody Binding ofgp120 and CD4.
￿
ELISAs were performed
by coatingplates with 10,ug/ml gp120 or, respectively, with 3,ug/ml
rCD4 and incubating them with serial dilutions of the mouse sera
starting at 1:100. Phosphatase-labeled goat anti-mouse (GAM) IgG
(Sigma Chemical Co.) was used to reveal bound antibodies. Readings
were performed in a Titertek automated photometer (Flow labora-
tories, Inc., McLean, VA).
Inhibition ofgp120 Binding to Solid-Phase CD4.
￿
After coating
the plates with 3-10 ug/ml rCD4, 50 td of gp120 (5 Icg/ml) was
added and incubated for 1 h, plus or minusserial twofold dilution
of test antiserum or antibody starting at 100,ug/ml concentration.
After washing, phosphatase-labeled monoclonal anti-gp120 was ap-
plied and incubated for 1 h. The phosphatase activity was then
measured by the rate of PNPP hydrolysis. The inhibition caused
by the test antibody was expressed in percent decrease from the
control gp120 binding.
Effect ofmAbs on CD4 Binding to Solid-Phase gpl20.
￿
Plates were
coated with 3 Fig/ml gp120. CD4-phosphatase at 10 and 3 Itg/ml
was incubated separately for 1 h with PTB (PBS [0.16 M, pH
7.2] containing 0.01% Tween 20 and 0.1% BSA) or with the test
mAbs at concentrations of0.3, 1, 3, and 10 Ag/ml. Then, the mix-
tures were added to the coated wells and incubated for 1 h. After
washing, the amount of bound CD4 was revealed by PNPP.
Effect ofgp120 on CD4 Binding to Solid-Phase Captured mAbs.
￿
In
separate 96-well plates, rgp120 and phosphatase-labeled rCD4 were
serially titrated by 10-fold dilution from 80 and 40 pg/ml, respec-
tively, in different directionson each plate. Equal volumes ofeach
were then combined and incubated 2 h at room temperature (RT).
Simultaneously with the above incubation, the test monoclonals
were added to a GAM IgG-coated platefor 2 h at RT, then washed
of excess sample. 50 pl of the titrated complex was transferred to
the captured mAb-GAM plate and incubated at RT for 2 h, and
then washed. PNPP substrate was added and the color was de-
veloped.
Effect ofgp120 on mAbs Binding to Solid-Phase CD4.
￿
Plates were
coated with 3 gg/ml rCD4. 25 pl of 0.1-1.0 hg/ml rgp120 and
25 P,1 of scalar concentrations (0.3-10.0 wg/ml) of test mAb were
added together to the wells and incubated for 2 h. After washing,
the bound mAb was revealed using GAM Ig phosphatase-labeled
antibody.
Crossinhibition ofCD4 Binding.
￿
Competition mapping of mAb
specificities was performed by coating plates with rCD4 and layering
alkaline phosphatase-labeled mAbs in the absence and presence of
graded concentrations ofunlabeled test mAbs whose specific binding
sites are known from the literature. OKT4A (binding in V1) and
OKT4 (binding in V4) were bought from OrthoDiagnostic Systems
Inc. (Westwood, MA); anti-Leu-3a (binding in V1), L83 (VI-V2),
L88 (V1), and L120 (V4) were gifts from Dr. David Buck, Becton
Dickinson & Co. (Mountain View, CA).
Inhibition ofSyncytia Formation.
￿
The cell fusion among CD4*
cell lines acutely infected by the virusrequires gp120-CD4-specific
binding. The test was performed according to Matthews et al. (10).
Briefly, CEM cells chronically infected with either HTLV3-IIIB or
HTLV3-RF were used for each determination. Sera diluted 1:10
'Abbreviations used in this paper: PNPP, paranitrophenylphosphate; RT,
room temperature; sCD4, soluble CD4.
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were distributed in 96-well A/2 plates (Costar, Cambridge, MA) .
5-10 x 103 HIVinfected cells were added. 7 x 10° uninfected
Molt 4 cells were admixed, and the plates were incubated over-
night at 37°C, after which the number of giant cells (more than
five times the size of the parental cells) were counted at 40x . The
mouse serum control varied from 60 to 85 giant cells per well.
Results
IlblyclonalResponses to Injection ofSoluble CD4 (sCD4}rgp120
Complexes in Mice. Three groups of four mice were injected
once, either with rCD4 alone (Fig. 1, A, D, and G), with
sCD4-rgp120 complex (Fig. 1, B, E, and H), or with rgp120
alone (Fig. 1, C, F, andI). The weekly bleedings were titrated
over a 3-mo period for capacity to bind CD4 (Fig. 1, D-F)
and gp120 (Fig. 1, A-C), and for capacity to inhibit the for-
mation of syncytia (Fig. 1, G-I). The overall results were
strikingly different among the three groups. Fig. 1 displays
the individual titers for each parameter and for each group.
There were often multiple peaks during the response (D),
and miceof a single group showed different timings for their
peaks (D and H). When the timing and magnitude of the
binding and neutralizing responses were examined: (a) there
was no clear correlation between the titers of gp120 binding
and syncytia blocking (B vs. H); (b) there was an inverse rela-
tionship between sCD4- and sCD4-rgp120-immunized groups
when sCD4 binding titers and syncytia blocking were com-
pared (D vs. G and E vs. H); or (c) there was a small CD4-
binding response in the group immunized with rgp120, which
could be attributed to antiidiotypes (F).
I-blyclonal Syncytia-blocking Responses by Mice Receiving CD4-
gp120 Complexes Are not Type Specific. The antisera from
mice injected with CD4-gp120 efficiently block synrytia for-
mation caused by such widely different HIV isolates as
HTLV3-IIIB and HTLV3-RF. Fig. 2 shows individual titra-
tions of the sera from these mice, revealing a similar rank
order of the individual responses against the two isolates
(93>94>91>92).
The Syncytia-blocking Capacity of CD4gpl20 Responders Is
Absorbed by CD4 and not by gp120. To determine whether
the high capacity of sera from complex-immunized mice to
inhibit synrytia formation was due to anti-CD4 or anti-gp120
antibodies (or to a cooperative action of the two), a series
of absorption experiments was performed using soluble and
solid-phase bound antigens. The samples were subsequently
monitored for changes in binding or synrytia-blocking titers.
The results unequivocally attributed the synrytia-blocking
capacity to antibodies that recognize the CD4 moietyof the
complex rather than anti-gp120, since absorbed anti-gp120
serum shows unaltered synrytia blocking, while the decrease
of CD4 binding is accompanied by a significant decrease of
synrytia blocking with both isolates tested (Table 1) .
The Capacity to Inhibit CD4-gp120 Binding In Vitro Corre-
lates with the CD4-binding Titerand not with the Syncytia-blocking
Titer . Since the synrytia-blocking capacity observed is medi-
ated by anti-CD4, the inverse relationship of binding and
synrytia-blocking titers in mice receiving CD4 vs. CD4-gp120
had to be attributed to a difference in the fine specificity of
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the anti-CD4 antibodies in the two groups. To further char-
acterize the anti-CD4 antibodies, one obvious test was to com-
pare their relative capacity to inhibit gp120 binding to CD4 .
The results (Table 2) showed high inhibition titers in all mice
immunized withCD4 alone and low titers in those immunized
with the CD4-gp120 complex, indicating that the blocking
of syncytia by the latter appears to be mediated by a mecha-
nism other than prevention ofbinding ofHIV to its receptor
on the cell surface.
Study ofAnti-sCD4-rgp120 Responses Using mAbs.
￿
To dis-
sect the polyclonal response of mice immunized with CD4-
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Figure 1 .
￿
The time course of an ex-
periment with three groups ofmice in-
jected withCD4 (A, D, and G), CD4-
gp120 complex (B, E, and H), and
gp120 (G, H, and 1) . The weekly serum
samples were assayed individually for
gp120-binding antibodies (A, B, and
C), CD4-binding antibodies (E), E, and
F), and syncytia-blocking capacity (G,
H, and 1) . The mice immunized with
the complex showeda somewhat higher
anti-gp120 response than those im-
munized with gp120 alone (B vs. C) ;
a markedly lower titer ofCD4 binding
as compared with those receiving CD4
alone (E vs. D); and a significantly
higher syncytia-blocking response (H
vs . G) .
Figure 2 .
￿
Titration of 11-wk serum
from four mice injected with CD4-
gp120 complex for 111B and RF
syncytia-blocking capacity. The parallel
behavior of individual sera in the two
tests suggests that the antibodies are
directed at group-specific determinants.
gp120 complex, hybridomas were produced from one of these
animals, and the resulting antibodies were characterized for
capacity to bind CD4, to bind gp120, and to block syncytia
formation . Table 3 shows an early test of 170 wells with hr
bridoma clones, ordered according to theirCD4 binding ca-
pacity. 30 (the majority) ofthe positive clones produced anti-
CD4; only four produced anti-gp120, and the remainder were
negative for both . Three of the anti-CD4 clones (and none
of the anti-gp120) exhibited capacity to block syncytia . All
borderline positives (i.e., those showing <0.100 in the gp120
binding) and those with partial blocking of syncytia (clonesTable 1.
￿
Absorption ofPooled Sera from Mice Immunized with
CD4-gp120, Demonstrating that Syncytia Blocking Is Associated
with anti-CD4
" OD4os/60 min (color developedby phosphatase hydrolysis of PNPP).
t Syncytia blocking assay as described in Materials and Methods.
116, 95, and 32) became negative after subcloning. Table 4
shows a further characterization of the hybridomas when the
inhibition of gp120-CD4 binding test was performed. The
anti-CD4 mAbs can be divided into three categories: (a) those
that do not inhibit gp120 binding and do not block syncytia;
(b) those that do not inhibit gp120 binding and block syn-
cytia; and (c) those that inhibit gp120 binding and block syn-
cytia. mAbs 55 and 94 were further studied as representa-
tives of the latter two categories, respectively. Both were of
IgG1 isotype.
Preliminary Mapping Experiments.
￿
The binding site ofboth
mAbs 55 and 94 was localized within the first two domains
(Vl-V2) of CD4 by binding experiments using the CD4 IgG
immunoadhesin (Genentech), which contains the two external
domains of CD4 spliced to an Ig C region (data not shown).
A crossinhibition experiment usinglabeled mAbs 94 and 55
was performed. The binding of these mAbs to solid-phase
CD4 was tested in the presence of a series ofanti-CD4 mAbs
whose epitopes and binding characteristics are known or par-
tially known from the literature. The two mAbs were not
inhibited by any of the tested antibodies with the exception
of L83, which showed a partial competition with mAb 55
(Table 5). These results do not provide a precise mapping
ofthe binding sitesofthe two mAbs. OKT4A and anti-Leu-
3a bind in the first domain of CD4, and the test shows that
neither binding site overlaps with mAbs 55 and 94. L83, ac-
cording to unpublished data (David Buck, personal commu-
nication), recognizes a conformational determinant that is
affected by mutations both in region 8-40 (Vl) and region
119-188 (V2). These data, taken together, indicate that the
fine specificity of mAbs 55 and 94 are different from most
studied antibodies and different from each other.
Interference ofgp120 with CD4 Binding by mAbs.
￿
Prelimi-
nary experiments had shown that mAb 94 blocked gp120
binding to CD4, while mAb 55 did not. To be able to detect
both inhibition and possible cooperativity between antibody
and gp120, we set up a series of three ELISAs by which the
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Table 2.
￿
Difference in Fine Specificity Distribution among
Polyclonal Anti-CD4 Antibodies
One blocking Uso is the amount of antibody that reduces to 50% the
amount of gp120bound to CD4-coated wellsor, respectively, thenum-
ber of syncytia in thefusion test. Uso/ml was calculated by multiplying
1 Uso by the dilution factor for each test.
ternary interaction of CD4, antibody, and gp120 was exam-
ined by keeping in turn one of the reactants in solid phase,
and varying the concentrations of the other two. The results
are shown in Figs. 3, 4, and 5, which also include curves
obtained with reference antibodies OKT4A (which competi-
tively interferes with CD4-gp120 binding) and OKT4 (which
does not). In Fig. 3, the binding of labeled CD4 to gp120
is slightly enhanced or nonsignificantly changed in the pres-
ence of increasing concentrations of 55, while it is progres-
sively inhibited by 94. In Fig. 4, the binding oflabeled CD4
to solid-phase captured antibody is increased 40% by gp120
in the case of 55 at the highest concentration of CD4, but
is unaffected or slightly decreased at lower concentrations of
CD4. In the case of 94, there is progressive decrease ofCD4
binding in the presence of increased gp120 concentrations,
more evident when CD4 is limiting. In Fig. 5, the binding
of labeled 55 to solid-phase CD4 is moderately enhanced in
the presence of 0.1 or 1.0 wg/ml gp120, while the binding
of 94 is depressed in these conditions.
The conclusions of this series of experiments are that: (a)
mAb 94 behaves always as an inhibitor/competitor of the CD4-
gp120 binding; and (b) mAb 55 in certain conditions does
not interfere with the binding in a way similar to OKT4,
while in other conditions, it shows a degree of cooperativity
with CD4-gp120 binding.
Discussion
It is known that the HIV infection of CD4+ cells can be
prevented by antibodies specific for the gp120-binding site
on CD4, defined as the Vl domain of CD4 involved in the
initial CD4-gp120-binding event, i.e., the region homolo-
gous to CDR2, amino acids41-52 (11-14), and in part CDR
3, amino acids 83-92 (15, 16). These antibodies prevent in-
fection by sterically interfering with the binding site.
We have obtained polyclonal and monoclonal antibodies
from mice immunized with CD4 complexed to gp120 and,
in this paper, we have described their binding characteristics
Monoclonal Antibody Anti-CD4 Blocks Events after HIV gp120 Binding
Absorbant CD4 binding gp120 binding
No.
syncytia#
IIIb
of
RF
OD' % OD'
None 1.216 (100) 0.940 (100) 0 3
gp120 1.180 (97) 0.188 (20) 0 5
CD4 0.420 (34) 0.936 (99) 11 24
No antiserum - - - - 52 60
Pool
CD4
binding
Blocking gp120
binding
Fusion
blocking
ftg/ml U50/ml" Uso1ml"
9 (immunized 2.4 80.0 45.0
CD4-gp120)
18 (immunized
CD4) 31.0 890.0 7.0Table 3.
￿
List of Hybridomas Obtainedfrom Fusion 91,
￿
and capacity to prevent the formation of HIVdependent syn-
Hierarchically Ordered According to their Supernatant's Capacity to
￿
cytia, while the study of their effect on cell-free virus infec-
Bind CD4, and Tested for Binding gp120 and Blocking Syncytia
￿
tion is in progress. The data presented here, and also results
Formation
￿
in other laboratories (Q Sattentau, personal communication),
demonstrate that there are epitopes on CD4, unrelated to
No. of
￿
the binding site of gp120, which antibodies can recognize,
Syncytia
￿
thus affecting post-virus-binding events that usually lead to
Clone Binding Binding
￿
at 1/2
￿
Syncytia
￿
ifectio . Molecular transitions can be relatively slow, and
it is conceivable that several successive steps, subsequent to
binding, may be susceptible to interruption. The finding that
anti-CD4 mAbs with different fine specificity show similar
behavior is consistent with this scenario.
Antibodies that recognize viral envelope proteins have been
shown to sometimes inhibit viral infection at a post-binding
step both in the case of HIV (4-6) and herpes viruses (7,
8). Several of these antibodies are directed at proteins that
mediate fusion of the viralenvelope with the cell membrane,
which normally results in virus penetration into the cytoplasm
(9). The antibodies apparently bind to the fusogenic protein
at a site that prevents its catalysis of the fusion event.
In the present case of HIV infection, it is not clear what
post-binding step is beingblocked. The bound antibody could
possibly prevent lateral migration of the CD4 receptor in the
plasma membrane preventing endocytosis, or block fusion
of the viral envelope with either the cell plasma membrane
or an endocytic vesicle membrane.
An alternative possibility is that the antibody may stabi-
lize an intermediate conformation of CD4 and prevent it from
reaching a stateconducive to membrane fusion. In general,
antibodies can stabilize a conformation, and thus stabilize
(or "freeze") the antigen in a state that provides the highest
affinity/lowest free energy to the paratope-epitope interac-
tion. This mechanism has been studied in the case of antibody-
mediated enzyme activation and stabilization, particularly in
the Escherichia coli fl-galactosidase system. The enzyme's tetra-
Table 4.
￿
Classification of mAbsfrom Mice Immunized with
CD4gp120 Complex
" OD405/120 min, when the supernatant was tested in ELISA on plates
coated with CD4 (respectively, gp120) (see Materials and Methods).
t Only numbers lower than the control are shown.
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Cut-off for a positive response was 25% blocking at a ;0 1:2 dilution.
nHybridoma designation CD4 gp120 dilution# blocking
1 135 1.363' 0"
144 1.208 0
148 1.149 0.007
75 1.059 0
215 1.049 0
145 0.982 0
84 0.932 0
142 0.930 0.012
140 0.837 0
10 210 0.724 0.015
185 0.672 0
143 0.599 0.009
201 0.482 0
J 0.437 0.006
203 0.398 0.006
15 0.385 0.010
156 0.372 0.028
58 0.313 0.011
224 0.308 0
20 146 0.255 0
55 0.182 0 9 80%
165 0.1 7 0
36 0.153 0.041 0 100%
172 0.145 0.006
94 0.136 0 0 100%
223 0.125 0
59 0.121 0
V 0.109 0
R 0.106 0.012
30 48 0.106 0
35 0 0.361
40 0 0.358
M (0.023) 0.176
68 0 0.116
116 (0.012) 0 16 65%
95 0 0 18 60%
32 0 0 18 60%
(control 46)
40
170 0 0
mAbs gp120 CD4 binding' syncitia blocking
Inhibiting
Binding Binding CD4-gp120 Group-specific
48, 35, 40 + - - -
68
135, 144, 148 - +
75, 215, 145
210, 185, 143
94, 36 - + + +
55 - + - +Table 5.
￿
Crossinhibition of CD4 Binding by mAbs 55 and 94
OKT4A Leu-3A L83 L88
rnAb 55
￿
-
￿
-
￿
±
mAb 94
￿
-
￿
-
￿
-
meric conformation is stabilized in an enzymatically active
state against denaturing conditions by polyclonal antibodies
(Fabs) raised against the native enzyme (17, 18). Antibodies
directed to a different epitope but present in the same an-
tiserum tend to restore the native conformation in mutants
defective in their differ-dimer cohesion (19, 20). On the other
hand, antibodies directed to the mutant configuration inhibit
the antibody-mediated activation process by freezing the mu-
tant conformation (21) .
There are two distinct (but not mutually exclusive) mech-
anisms that could cause the differences observed between the
polyclonal response ofmice immunized with sCD4 vs. sCD4-
rgp120 complex. One is the modification of the processing/
presentation of the CD4 antigen because of its uptake in the
form of a tightly bound complex with gp120. By analogy
with what is known in the case of antibody-antigen com-
plexes (22, 23), the presence of the ligand can affect the en-
zymatic breakdown of the immunogen and consequently the
presentation of various peptides on class II MHC molecules.
Consequently, the population of T specificities activated would
differ in the two cases, and so would the T help for the var-
ious antibody-forming cells that can recognize CD4 epitopes.
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antibody concentrations (jug/ml)
L92 L120 OKT4 F91-55 F91-94 F91-36
" Cut-off point for positivity was 25% or larger decrease in binding when the inhibitor was six times more concentrated than the test mAb.
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Figure 3. Effect of antibodies on
rCD4-phosphatase binding to solid-
phase rgp120. (A) OKT4A antibody;
(B) 94 antibody; (C) OKT4 antibody;
(D) 55 antibody.CD4-phosphatase con-
centrations: (") 10 ug/ml; (O) 3 Ig/
ml. (y-axis) OD4os/60 min; (x-axis)
antibody concentration, from left to
right, 0, 0.3, 1, 3, and 10 Ag/ml.
The second, more direct possibility is an effect or combi-
nation ofeffects of the ligand on the B epitopes of the rCD4
molecule. For instance, the lower binding titers in mice in-
jected with sCD4-rgp120 could be attributed to a "blanketing"
effect of the large gp120 molecule over the relatively small
CD4, many of whose epitopes would be hidden and thus
unable to interact with the B cell surface Igs. In addition,
the qualitative differences could be attributed to the appear-
ance (caused by the binding of rgp120) of new or modified
conformational epitopes that are absent or less represented
in free molecules.
One aspect of the present results that should be noted is
that the polyclonal response showed greater relative efficiency
of syncytia blocking than the mAbs. This means that the
small mAb population does not faithfullyrepresent the clones
active in the animals. It also supports the prediction that more
varieties ofantibodies recognizing intermediate epitopes, and
thus possessing a greater ability to discriminate critical steps
in the infection process, will be obtained by enlarging the
number of immunized mice and the number of mAbs pro-
duced from them.OD 405:
0 .800
0 .700-
0.600
0.500
0.400
0 .300-
0 .200-
0 .100
0 0 .4 4 40 0 0 .4 4 40 0 0.4 4 40 0 0 .4 4
gp1I20 concentrations (tug/mi)
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Figure 4.
￿
Effect ofrgp120on rCD4-
phosphatase binding to various anti-
bodies captured on solid-phaseGAMIg.
(A) OKT4Aantibody; (B)94 antibody;
(C) OKT4 antibody; (D) 55 antibody.
Concentration of rCD4-phosphatase:
(0) 10 ttg/ml; (O) 1 Fog/ml; (N) 0.1
kg/ml. (y-axis) OD405/60 min (A and
B) or OD4os/120 min (C and D); (x-
axis) concentration of gp120(0, 0.4,4,
and 40 Fog/ml).
Figure 5.
￿
Effect ofrgp120 on phos-
phatase-labeled antibody binding to
solid-phase rCD4. (A) 94 antibody; (B)
55 antibody. (O) No rgp120; (")
rgp120 at 0.1 Ug/ml; (N) rgp120 at
1.0 Ftg/ml. (y-axis) OD4o5/60 min; (x-
axis) antibody concentrations (0.1, 1,
3, and 10 Wg/ml).
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